Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
Research indicates BPX-01 may offer safe, effective treatment
Jan 15, 2016
MENLO PARK, Calif., Jan. 15, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at the 2016 Winter Clinical Dermatology Conference next week shows its unique formulation of minocycline, known as BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
Minocycline is the antibacterial and anti-inflammatory medicine most commonly prescribed to treat acne. However it is typically used orally because no one has found a way to produce an effective minocycline-based topical medication. BPX-01 is the first and only stable hydrophilic (non-oil-based) topical gel formulation with fully solubilized minocycline that effectively delivers the antibiotic to the source of the acne.
Results from a preclinical toxicology study demonstrate that both systemic exposure and peak plasma concentrations of minocycline are minimized by topical administration, which eliminates the risk of unwanted side-effects associated with oral minocycline, including diarrhea, nausea, and dizziness that can discourage compliance.
Study findings will be presented Monday at the Winter Clinical Dermatology Conference, being held in Koloa, Hawaii, Jan. 15-20.
"The topical administration of minocycline via BPX-01 delivers the antibiotic to the specific layer of skin where acne develops, but does not result in a significant concentration of the drug in the system, suggesting that it may offer dermatologists a safer way to treat the condition," said Kin F. Chan, Ph.D., executive vice president of research and development at BioPharmX Corporation. "The preclinical studies suggest that this targeted delivery of minocycline virtually eliminates any risk of systemic side effects."
Most topical acne medications available today use less effective antibiotics than minocycline. However, many are lipophilic (oil based), which means they cannot effectively deliver even the less effective antibiotic to the epidermis and the pilosebaceous region where acne develops.
The BioPharmX research also found that its hydrophilic BPX-01 formulation distributes evenly, is not sticky and does not occlude or irritate the skin, an advantage in the treatment of acne.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans at any given moment. The disease can cause permanent scarring, low self-esteem, depression and anxiety.
About BioPharmX™ Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by those section. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding, including with respect to: the success of the commercialization of VI2OLET iodine, the effectiveness of BPX01, the timing with respect to filing an IND and clinical trials for BPX-01, the release of key data for BPX01, the release of key data and the successful completion of multi-site IRB studies for BPX03 and the successful completion of the private placement with Korea Investment Partners Overseas Expansion Platform Fund. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
BioPharmX and Violet are registered trademarks of BioPharmX, Inc.
SOURCE BioPharmX Corporation
For further information: Nina Brauer, Senior Manager, Marketing & Communications, email@example.com, (650) 889-5030 OR Jim Martinez, RightStoryGroup LLC, firstname.lastname@example.org, (312) 543-9026